88 citations,
May 2011 in “British Journal of Clinical Pharmacology” High doses of cyproterone acetate are linked to an increased risk of developing meningioma.
34 citations,
November 2017 in “Gynecological Endocrinology” A transwoman developed a brain tumor after nine years of hormone therapy, suggesting a possible link between the treatment and tumor development.
5 citations,
June 2021 in “Journal of neurology, neurosurgery and psychiatry” Taking high doses of Cyproterone acetate significantly increases the risk of meningioma in females.
59 citations,
February 2021 in “BMJ” High doses of cyproterone acetate increase the risk of brain tumors in women, but the risk decreases after stopping the medication.
January 2024 in “Pharmaceutical medicine” Most European physicians know the risks and safe use of Cyproterone acetate, but few remember receiving official safety communications.